~~WHAT IS~~ CLAIM~~ED I~~S:

1. A crystalline form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, substantially free of other polymorphic forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate.

2. The crystalline form of claim **1**, wherein said crystalline form is anhydrous 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate ("Form I"), and characterized by having a melting point of about 253°C, and an aqueous solubility of about 8.3 mg/mL at 25°C ~~("Form I")~~.

3. The crystalline form of claim **1~~2~~**, wherein said crystalline form is Form I, ~~is~~ characterized by an X-ray powder diffraction (XRPD) pattern that comprises peaks at 10.0, 18.1, 18.6, 20.1, and 23.9 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

4. The crystalline form of claim **3**, wherein the XRPD pattern further comprises a peak at 20.5 degrees, ± 0.5 degrees, 2θ.

5. The crystalline form of claim **3** or **4**, wherein the XRPD pattern is substantially similar to the pattern of Figure 1.

~~**6**. The crystalline form of claim **1**, wherein said 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate is hydrated, and characterized by having a melting point of about 253°C and an aqueous solubility of about 5.5 mg/mL at 25°C ("Form II").~~

~~7~~6. The crystalline form of claim **1~~6~~**, wherein said crystalline form is Form II, ~~is~~ characterized by an XRPD pattern that comprises peaks at 4.2, 5.6, 8.4, 17.8, and 19.8 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

~~8~~7. The crystalline form of claim ~~7~~**6**, wherein the XRPD pattern further comprises a peak at 12.7 degrees, ± 0.5 degrees, 2θ.

~~9~~8. The crystalline form of claim **6~~7~~** or **7~~8~~**, wherein the XRPD pattern is substantially similar to the pattern of Figure 2.

~~10. The crystalline form of claim 1, wherein said 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate is anhydrous, and is characterized by having a melting point of about 249°C, and an aqueous solubility of about 7.2 mg/mL at 25°C ("Form III").~~

~~11~~9. The crystalline form of claim 1~~0~~, wherein said crystalline form is Form III~~, is~~ characterized by XRPD pattern that comprises peaks at 7.7, 10.7, 20.1, 23.7, and 24.3 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

~~12~~10. The crystalline form of claim ~~11~~9, wherein the XRPD pattern further comprises peaks at 18.5 and 26.5 degrees, ± 0.5 degrees, 2θ.

11~~13~~. The crystalline form of claim ~~11~~ 9 or ~~12~~10, wherein the XRPD pattern is substantially similar to the pattern of Figure 3.

~~14~~12. The crystalline form of claim **1**, wherein said crystalline form is Form IV 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate~~, characterized by having a melting point of about 251°C, and characterized by~~ an XRPD~~)~~ pattern that comprises peaks at 18.5, 19.6, and 23.7 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation ~~("Form IV")~~.

~~15. The crystalline form of claim 14, wherein the XRPD pattern further comprises a peak at 24.6 degrees, ± 0.5 degrees, 2θ.~~

~~16. The crystalline form of claim 14 or 15, wherein the XRPD pattern is substantially similar to the pattern of Figure 4.~~

~~17~~13. An amorphous form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, characterized by having a melting point of about 240°C, and an aqueous solubility of about 7.1 mg/mL in water at 25°C ("Form V").

~~18~~14. A pharmaceutical composition ~~for the treatment of a plasma kallikrein-dependent disease or condition~~, comprising a ~~therapeutically effective amount of the~~ solid form of any one of claims **1** to ~~17~~13, and a pharmaceutically acceptable carrier.

~~**19**. The pharmaceutical composition of claim **18**, wherein the solid form is the Form I of any one of claims **2** to **5**, and a pharmaceutically acceptable carrier.~~

~~**20**. The pharmaceutical composition of claim **18**, wherein the solid form is the Form II of any one of claims **6** to **9**, and a pharmaceutically acceptable carrier.~~

~~**21**. The pharmaceutical composition of claim **18**, wherein the solid form is the Form III of any one of claims **10** to **13**, and a pharmaceutically acceptable carrier.~~

~~**22.** The pharmaceutical composition of claim **18**, wherein the solid form is the Form IV of any one of claims **14** to **16**, and a pharmaceutically acceptable carrier.~~

~~**23.** The pharmaceutical composition of claim **18**, wherein the solid form is the Form V of claim **17**, and a pharmaceutically acceptable carrier.~~

~~24~~15. A method for making the Form I of any one of claims **2** to **5**, comprising:

contacting a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate with a solvent selected from the group consisting of methanol, ethanol, isopropanol, tetrahydrofuran, 2-methyl-tetrahydrofuran, anhydrous acetone, dichloromethane, diethyl ether, 3-methyl-1-butanol, and nitromethane, or a mixture thereof, for a period of time sufficient to produce Form I.

~~**25.** The method of claim **24**, wherein the solvent is methanol.~~

~~**26**. The method of claim **24** or **25**, wherein the solvent further comprises a solvent selected from the group consisting of tetrahydrofuran, t-butyl-methyl ether, and heptane.~~

~~**27**. A method for making the Form II of any one of claims **6** to **9**, comprising:~~

~~contacting a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate with a mixture of water and a solvent selected from the group consisting of isopropanol, tetrahydrofuran, acetone, and ethyl acetate, or a combination thereof, for a period of time sufficient to produce Form II.~~

~~**28**. The method of claim **27**, wherein the mixture comprises at least about 10% water.~~

~~**29**. The method of claim **27** or **28**, wherein said solvent is ethyl acetate.~~

~~**30**. A method for making the Form V of claim **17**, comprising:~~

~~(a) dissolving a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate in a sufficient quantity of water to form a solution;~~

~~(b) freezing the solution; and~~

~~(c) lyophilizing the product of step (b).~~

~~**31**. A method for making the Form III of any one of claims **10** to **13**, comprising:~~

~~contacting a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate with acetonitrile for a period of time sufficient to produce Form III.~~

~~**32**. The crystalline form of claim **1**, having less than 10% by weight of any other polymorphic form.~~

~~**33**~~**16**. The crystalline form of any of claims 1 to **13**~~**32**~~, having less than 5% by weight of any other polymorphic form.

~~**34**~~**17**. The crystalline form of any one of claims 1 to **13**~~**32** or **33**~~, having less than 1% by weight of any other polymorphic form.

~~35~~**18**. Use of the crystalline form of any one of claims **1** to **13**, or the pharmaceutical composition of claim **14**, in the preparation of a medicament ~~A method~~ for treating of a plasma kallikrein-dependent disease or condition~~, comprising:~~

~~administering an effective amount of the crystalline form of any one of claims **1** to **17**, or the pharmaceutical composition of any one of claims **18** to **23** to~~ in a subject in need thereof.

~~36~~**19**. The ~~method~~ use of claim ~~35~~**18**, wherein the plasma kallikrein-dependent disease or condition is selected from the group consisting of:

diabetic macular edema, diabetic retinopathy, hereditary angioedema with C1 inhibitor deficiency, acute liver injury, inflammation, anaphylaxis, chemical-sensitized renal damage, ischemic stroke, hemorrhagic stroke, hypertension, vascular complications of hypertension, retinopathy, nephropathy, cerebrovascular edema, pulmonary hypertension, inflammation, pain, acute myocardial infarction, deep vein thrombosis, complications from fibrinolytic treatment, angina, angioedema, sepsis, arthritis, complications of cardiopulmonary bypass surgery, capillary leak syndrome, inflammatory bowel disease, diabetes, diabetic retinopathy, diabetic macular edema, diabetic nephropathy, diabetic neuropathy, age-related macular degeneration, retinal vein occlusions, brain edema, ischemia-reperfusion injury, cancer-related angiogenesis, asthma, anaphylaxis, and cerebrovascular complications of Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, Central Nervous System infections, and glioblastoma multiforme.

~~**37**. The use of a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, substantially free of other polymorphic forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, for the treatment of a plasma kallikrein-dependent disease or condition.~~

~~**38**. The use of claim **37**, wherein the solid form is the form of any one of claims **1** to **17**.~~

~~**39**. The use of a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, substantially free of other polymorphic forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, for the manufacture of a medicament for the treatment of a plasma kallikrein-dependent disease or condition.~~

~~**40**. The use of claim **39**, wherein the solid form is the form of any one of claims **1** to **17**.~~

~~**41**. The crystalline form of any one of claims **3, 4, 7. 8, 11, 12, 14, 15,** wherein the XRPD peaks are within ± 0.2 degrees 2θ of the stated peak position.~~

~~**42**. The crystalline form of claim **41**, wherein the XRPD peaks are within ± 0.1 degrees 2θ of the stated peak position.~~